#News for #investors & #media: Today marks an important milestone in chronic hepatitis B (CHB), with the U.S. FDA approving a new therapy for people living with the disease. This approval reflects years of research and a continued commitment to advancing innovation in liver disease, where significant unmet need remains. Learn more: gsk.to/4Bisj2s

#News for #Investors and #Media: The US Food and Drug Administration (FDA) has approved a new indication for one of our immunotherapies. Read more: gsk.to/4iwAy2D

#News for #Investors and #Media: Today, we shared the first data for our investigational treatment for extensive-stage small-cell lung cancer in a global population. Learn more: gsk.to/4z38aw4 #ESMO2026

#News for #Investors and #Media: At ESMO 2026, we're showcasing over 20 abstracts from our oncology portfolio and pipeline, underscoring our expansion into solid tumours like lung, gynaecological, gastrointestinal, and GIST. Read more:gsk.to/4dCmnr6 #ESMO2026

Dementia is one of the greatest health challenges facing society today. We're proud to support The BARBARA Alliance in a major new partnership, announced today by UK Government, bringing together academia, charities and industry to help accelerate research. Read more here: gsk.to/4doDhJG

#News for #Investors and #Media: Today our specialist HIV company, @ViiVHC, announced phase III study results in #HIV evaluating a long-acting option versus daily oral therapy. Our mission: to leave no person living with HIV behind. 👉 Find out more: gsk.to/3VpWIM1

#News for #investors and #media: We have entered a licence agreement with Chimagen Biosciences for an investigational T-cell engager for multiple myeloma, advancing our leadership ambitions in blood cancer. Find out more: gsk.com/en-gb/media/press-re…

#News for #investors and #media: Today, we announced new positive data at #WCLC26 representing encouraging news for people living with ROS1-positive non-small cell lung cancer. Learn more: gsk.to/4xolucI

#News for #investors and #media: Today, our licensor Hansoh Pharma presented positive data at #WCLC26 from a pivotal trial of an investigational antibody-drug conjugate in our pipeline. Learn more: gsk.to/4xRUa7t

#News for #Investors and #Media: Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a new prefilled syringe presentation of one of our vaccines. Learn more: gsk.to/4xSAW1Q

The data we’ve shared at #ERSCongress underscores how much more we can achieve for respiratory patients when science and partnership come together. Building on our proven track record of innovation, we’re accelerating our R&D programmes in COPD to target multiple inflammatory pathways, aiming for ambitious trial outcomes that look beyond the disease impact on the lungs so that we can transform outcomes for a broad range of patients, with varying severities of disease. #ERSCongress

#Media #Investors Climate change is one of the greatest threats to human health, and its impact on patients with respiratory health conditions should not be underestimated. Through advances in sustainable respiratory care, we’re making progress towards our environmental goals. Read the media statement gsk.to/4iFXSfO

#News for #Investors and #Media: Today we announced Phase II data for a seasonal flu vaccine candidate at #OPTIONSXIII. Learn more: gsk.to/3Sqbt0e

#News for #investors & #media: Japan has become the first country to approve a new therapy for people living with chronic hepatitis B (CHB), marking an important milestone in liver disease innovation. CHB remains a leading cause of liver cancer worldwide. This approval reflects continued commitment to progress in liver disease research. Learn more: gsk.to/4wNSLxB

#News for #Investors and #Media: Today, we announced the US FDA accepted the application for one of our immuno-oncology therapies for priority review. Learn more: gsk.to/4zAczXU

#News for #Investors and #Media: At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline for #HIV treatment and prevention, through our specialist HIV company, @ViiVHC. Find out more: gsk.to/44YUip5

Yesterday we announced we will be establishing a new flagship R&D centre on the Cambridge Biomedical Campus. This will feature state-of-the-art, tech-enabled labs and infrastructure, providing GSK scientists with access to a world-class ecosystem of biomedical research, patient care and academia as part of a £400 million investment in UK life sciences. Learn more gsk.to/4hE7vuR

#Investors: Join our webcast (14:00 BST, 09:00 EST) to hear our CEO Luke Miels and other members of our senior leadership team including R&D experts talk about our Q2 2026 results and plans to accelerate growth. $GSK

Today, we’re announcing a £400 million investment in UK life sciences, including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D.